Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-523070-16-00
Authorised, not yet recruiting Phase IV

Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population

2025-523070-16-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Laboratory/Research/Testing facility
Therapeutic area
Nervous System Diseases
Decision date
31/08/2026
Enrollment target
80
Sites
Spain

Condition studied

Postoperative delirium

Investigational medicinal product(s)

Dexdor 100 micrograms/ml concentrate for solution for infusionPropofol Lipuro 20 mg/ml emulsión inyectable y para perfusión

Every trial of Propofol and Dexmedetomidine across our registers →

Eligibility

Age group
65+ years
Sex
Female, Male

Primary endpoint

Prevalence, severity, and course of delirium during the postoperative period.

Endpoint detail

Clinical and epidemiological data, including factors associated with the onset of postoperative delirium., Sedative medications and administered doses, degree and quality of sedation as measured by the RASS scale (Appendix 1), events during sedation (episodes of agitation, need for restraint, etc.), and depth of sedation (BIS)., Clinical parameters (BP, SpO₂, HR, EtCO₂), basic laboratory tests (hemoglobin, electrolytes, blood glucose, and inflammatory markers such as CRP), and intra- and postoperative events (bleeding, blood product transfusion, hypertension/hypotension, desaturation, apnea, etc.)., Pain assessment (PA) and analgesia administered during the perioperative and postoperative periods.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523070-16-00 on CTIS ↗ ← All trials in the EU